XML 70 R30.htm IDEA: XBRL DOCUMENT
v3.25.1

Collaboration and License Agreements - Additional Information (Details) $ / shares in Units, $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2025 USD ($) undisclosedProgram geneTherapyProgram preclinicalCandidate non-clinicalStageCompound | Mar. 31, 2024 USD ($) | Mar. 31, 2023 $ / shares shares | Dec. 31, 2022 $ / shares shares | Dec. 31, 2021 $ / shares shares | Dec. 31, 2019 $ / shares shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Total revenues | $ 572.6 | $ 515.3 |  |  |  |
Collaborative Arrangement | Common Stock | Voyager |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Beneficial ownership (as a percent) |  |  | 19.90% |  |  |
Nxera | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | $ 2,500.0 |  |  |  |  |
Agreement termination, minimal contractual time (in days) | 180 days |  |  |  |  |
Agreement termination, contractual time threshold (in days) | 90 days |  |  |  |  |
Agreement termination by counterparty, contractual time threshold (in days) | 365 days |  |  |  |  |
Agreement termination by counterparty, minimal contractual time (in days) | 120 days |  |  |  |  |
Takeda | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | $ 700.0 |  |  |  |  |
Agreement termination, minimal contractual time (in days) | 6 months |  |  |  |  |
Agreement termination, contractual time threshold (in days) | 12 months |  |  |  |  |
Number of non-clinical stage compounds | non-clinicalStageCompound | 3 |  |  |  |  |
Research and development | $ 37.5 |  |  |  |  |
Xenon | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | $ 1,700.0 |  |  |  |  |
Agreement termination, contractual time threshold (in days) | 90 days |  |  |  |  |
Research and development | $ 7.5 |  |  |  |  |
Number of preclinical candidates | preclinicalCandidate | 3 |  |  |  |  |
Sale of stock (in shares) | shares |  |  |  | 300,000 | 300,000 | 1,400,000
Share price (in USD per share) | $ / shares |  |  |  | $ 31.855 | $ 19.9755 | $ 14.196
Voyager | Collaborative Arrangement | Common Stock |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Sale of stock (in shares) | shares |  |  | 4,400,000 |  |  | 4,200,000
Transfer, beneficial ownership, and voting restrictions period (in years) |  |  | 3 years |  |  |
2019 Voyager Agreement | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | $ 1,300.0 |  |  |  |  |
Agreement termination, minimal contractual time (in days) | 180 days |  |  |  |  |
Agreement termination, contractual time threshold (in days) | 1 year |  |  |  |  |
Research and development |  | 5.0 |  |  |  |
Share price (in USD per share) | $ / shares |  |  |  |  |  | $ 11.9625
Number of undisclosed programs | undisclosedProgram | 2 |  |  |  |  |
2023 Voyager Agreement | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | $ 6,100.0 |  |  |  |  |
Agreement termination, minimal contractual time (in days) | 180 days |  |  |  |  |
Agreement termination, contractual time threshold (in days) | 1 year |  |  |  |  |
Share price (in USD per share) | $ / shares |  |  | $ 8.88 |  |  |
Number of gene therapy programs | geneTherapyProgram | 3 |  |  |  |  |
Board of directors maximum duration term (in years) |  |  | 10 years |  |  |
Sanofi S.A | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | $ 10.0 |  |  |  |  |
Sanofi S.A | Collaborative Arrangement | Minimum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Royalties at tiered percentage | 3.00% |  |  |  |  |
Sanofi S.A | Collaborative Arrangement | Minimum | Patents |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Patent term (in years) | 16 years |  |  |  |  |
Sanofi S.A | Collaborative Arrangement | Maximum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Royalties at tiered percentage | 5.00% |  |  |  |  |
MTPC | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Agreement termination, contractual time threshold (in days) | 180 days |  |  |  |  |
Potential milestone payment receipts | $ 30.0 |  |  |  |  |
MTPC | Collaborative Arrangement | Minimum | Patents |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Patent term (in years) | 10 years |  |  |  |  |
AbbVie | Collaborative Arrangement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Agreement termination, contractual time threshold (in days) | 180 days |  |  |  |  |
Potential milestone payment receipts | $ 366.0 |  |  |  |  |
AbbVie | Collaborative Arrangement | Royalty |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Total revenues | $ 6.7 | $ 3.0 |  |  |  |
AbbVie | Collaborative Arrangement | Minimum | Patents |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Patent term (in years) | 10 years |  |  |  |  |

X
- Definition Agreement Termination By Counterparty, Contractual Time Threshold + References No definition available. + Details
Name: | nbix_AgreementTerminationByCounterpartyContractualTimeThreshold
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement Termination By Counterparty, Minimal Contractual Time + References No definition available. + Details
Name: | nbix_AgreementTerminationByCounterpartyMinimalContractualTime
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement Termination, Contractual Time Threshold + References No definition available. + Details
Name: | nbix_AgreementTerminationContractualTimeThreshold
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement Termination, Minimal Contractual Time + References No definition available. + Details
Name: | nbix_AgreementTerminationMinimalContractualTime
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Board Of Directors Maximum Duration Term + References No definition available. + Details
Name: | nbix_BoardOfDirectorsMaximumDurationTerm
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Royalties At Tiered Percentage + References No definition available. + Details
Name: | nbix_MilestoneRoyaltiesAtTieredPercentage
Namespace Prefix: | nbix_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Gene Therapy Programs + References No definition available. + Details
Name: | nbix_NumberOfGeneTherapyPrograms
Namespace Prefix: | nbix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Non-clinical Stage Compound + References No definition available. + Details
Name: | nbix_NumberOfNonClinicalStageCompound
Namespace Prefix: | nbix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Preclinical Candidates + References No definition available. + Details
Name: | nbix_NumberOfPreclinicalCandidates
Namespace Prefix: | nbix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Undisclosed Programs + References No definition available. + Details
Name: | nbix_NumberOfUndisclosedPrograms
Namespace Prefix: | nbix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | nbix_PatentTerm
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of potential milestone payment receipts under a collaborative arrangement. + References No definition available. + Details
Name: | nbix_PotentialMilestonePaymentReceipts
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of potential milestone payments under a collaborative arrangement. + References No definition available. + Details
Name: | nbix_PotentialMilestonePayments
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares sold by the collaboration partner per stock transaction. + References No definition available. + Details
Name: | nbix_SaleOfStockNumberOfSharesSoldInTransaction
Namespace Prefix: | nbix_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period remaining for contractual sale restriction on equity security measured at fair value with change in fair value recognized in net income (FV-NI), subject to contractual sale restriction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes investment in equity security by investment company for which discount for contractual sale restriction is applied. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B + Details
Name: | us-gaap_EquitySecurityFvNiContractualSaleRestrictionRemainingPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_NxeraPharmaUKLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_A2019VoyagerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_A2023VoyagerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_SanofiS.AMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbix_AbbVieIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |